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medicines in The Netherlands requires data collection on actual use
and cost-effectiveness after the initial decision to reimburse a drug.
This introduces new sources of uncertainty (less important in a
randomized controlled trial than in daily practice), which may affect
priorities for further research. Objectives: This article focuses on
determining the impact of including these uncertainties at the time
a decision is made, and whether more complex models are always
needed to address prioritization of additional research. Methods: We
constructed a typical decision model for chronic progressive diseases
with four health states and parameters related to transition and
exacerbation probabilities, costs, and utilities. Different scenarios are
built on the basis of three additional uncertainties: persistence,
compliance, and broadening of indication. Persistence refers to treat-
ment duration. Compliance describes the fraction of treatment beneﬁt
obtained because of not taking the medication as prescribed.
Broadening of indication reﬂects a shift in the severity distribution atee front matter Copyright & 2015, International S
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00 DR Rotterdam, The Netherlands.treatment start. These uncertainties were parameterized in the model
and included in the value-of-information analysis. Results: The most
important parameters were transition probabilities. Broadening of
indication had little impact on the overall uncertainty. Compliance
and persistence were important when establishing priorities for
further research. Major differences with respect to the reference
scenario were due to the parameterization of compliance in the
decision model. Conclusions: The usual practice of modeling only
randomized controlled trial data at the time the decision on condi-
tional reimbursement is made can lead to wrong decisions. Additional
uncertainties arising from outcomes studies should be anticipated at
an early stage and included in the model because this can have a
strong impact on the prioritization of further research.
Keywords: conditional reimbursement, decision model, research
prioritization, structural uncertainty, value of information.
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Decision models are used to assess the cost-effectiveness of a
new treatment or health care technology and also to provide
information about the need to collect additional data and set
priorities for future research using value-of-information (VOI)
analysis. In particular, VOI analysis is identiﬁed as a crucial tool
when judging whether or not to postpone a decision about the
reimbursement of new drugs [1–4] and it becomes more useful
when different sources of uncertainty are properly characterized
in the decision model [5]. In The Netherlands, there is still little
experience with VOI analysis and its interpretation in reimburse-
ment and priority setting. Nevertheless, the concept of condi-
tional reimbursement, introduced by the Dutch authorities,
represents an excellent opportunity to study the usefulness of
VOI analysis within its natural framework. In the Dutch condi-
tional reimbursement setting, it is established that policymakers
have to make a decision about the conditional reimbursement ofa new treatment at the time a reimbursement dossier is sub-
mitted. These dossiers usually include a decision model that is
used to assess the cost-effectiveness of the new treatment. Such
models usually try to mimic what is observed in the registration
randomized controlled trials (RCTs) as closely as possible, and
usually little attention is paid to translating the trial efﬁcacy into
real-life effectiveness. To better understand what the cost-
effectiveness of the drug will be in daily practice, the Dutch
authorities have determined that data on the actual effectiveness
of a new drug, rather than efﬁcacy, need to be collected in an
outcomes study during a period of conditional reimbursement.
The length of this period is negotiable and depends, for example,
on the time it takes to set up a patient registry and on the time it
takes to collect sufﬁcient information on health outcomes. It is
important to realize that in the beginning of the reimbursement
procedure the decision model may underestimate uncertainty,
not only because some uncertainty is simply not (yet) para-
meterized but also because the estimates of uncertainty thatociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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based on RCTs. For example, in the context of the Dutch condi-
tional reimbursement of medicines, compliance is mostly dis-
regarded in the analysis when the reimbursement procedure
starts because compliance is usually very high in clinical studies.
It is expected, however, to be important in effectiveness out-
comes studies [6]. We may consider that for certain treatments
(such as chemotherapy) compliance in an outcomes study will
also be high and thus comparable to the compliance in an RCT.
But for some other treatments, such as drugs aiming at the
secondary prevention of disease worsening or complications, this
might not be the case and compliance is likely to be much lower
in daily practice. On top of that, the population of an RCT is often
more homogeneous than the population in an outcomes study.
Because RCTs usually have strict inclusion and exclusion criteria,
the study population may be limited to patients without comor-
bidities, in a particular age group or with a certain disease
severity. In daily practice, the target group may be broadened,
which leads to more heterogeneity, as a result of which the
treatment effect observed in an outcomes study differs signiﬁ-
cantly from the treatment effect observed in an RCT. Therefore,
data collected from RCTs are usually considered as inappropriate
to describe routine use [7–9].
It is clear that by collecting data from an outcomes study, new
sources of uncertainty that are not present (or minimized) in an
RCT are introduced. These additional uncertainties are usually
not parameterized in the decision model included in the initial
reimbursement dossier. As we will show in this article, policy-
makers should wonder how to anticipate them and ask the
researchers to include extra parameters in the initial model to
account for these uncertainties. The decision model with the
additional uncertainties should then again be used when the
dossier is resubmitted after the period of conditional reimburse-
ment is ﬁnished. Although the speciﬁc additional uncertainties to
be modeled will vary from decision problem to decision problem,
in the present study we have opted to consider three often
relevant parameters, that is, persistence, compliance, and broad-
ening of indication, as extra uncertainties observed in an out-
comes study. Persistence refers to the duration of treatment (e.g.,
number of patients following the treatment after a certain time
and number of days until treatment discontinuation), and it is
determined here by the probability of discontinuing the treat-
ment over time. Compliance to medication is related to the degree to
which patients take the medication as it was prescribed (which is
assumed to provide an optimal treatment beneﬁt). Compliance is
characterized here by the fraction of the (treatment) beneﬁt
obtained because of not taking the medication as it had been
indicated (i.e., patients do not get a full beneﬁt of it). Finally, a
broadening of indication is considered. What often happens
when indication is broadened is that patients who are less severe
than the patients in clinical trials also become eligible for the
treatment. Therefore, the proportion of less severely ill patients
in the total population increases. Broadening of indication is
implemented here as a shift in the severity distribution at the
start of the treatment.
Only when these extra uncertainties are directly parameter-
ized in the decision model we can include them in a VOI analysis.
This way, we can measure the impact of the additional uncer-
tainties that arise from doing an outcomes study in the overall
uncertainty of the model and decide whether further research
would help to resolve them. The inclusion of additional param-
eters, however, increases the complexity of the decision model.
Thus, besides determining the impact of including additional
parameters at the time a decision is made about conditional
reimbursement, we explore whether more complex models are
always needed to properly inform the question about prioritizing
additional research.Methods
Model and Interventions
We have constructed a decision model that is typical for a
chronic progressive disease. Patients can be in four different
health states: moderate, severe, very severe, and dead. The
disease progression is described by a Markov model similar to
the one introduced by Vemer et al. [10]. The model is set up for 36
cycles of 1 month. In each cycle, patients can move to another
disease state or remain in the same one. Once patients die, they
remain in that health state. The proportional severity distribution
at cycle 1 is the following: 62.5% (moderate), 25% (severe), 12.5%
(very severe), and 0% (dead). Patients can also experience an
exacerbation, that is, an episode of disease worsening. Effects
(utilities) and costs are assigned to the different disease states. In
addition, each exacerbation leads to extra costs and utility
decrement. The main outcome of this model is the cost per
quality-adjusted life-year (QALY) gained over a time period of
3 years.
In the model, there are two interventions being compared,
which are referred to simply as usual care and new treatment. It
was assumed that compared with the natural disease progres-
sion, which means no treatment, both interventions decrease the
probability of moving to a worse health state and the probability
of experiencing an exacerbation, in which this decrease is higher
for new treatment. Both usual care and new treatment have
associated costs per cycle. Usual care (€175 per cycle) is cheaper
than new treatment (€225 per cycle). These intervention costs are
assumed to be normally distributed. Transition probabilities were
assumed to follow Dirichlet distributions, whereas the exacerba-
tion probability associated with each health state was modeled as
a beta random variable. We also assumed that utilities, main-
tenance and exacerbation costs, and utility changes due to
exacerbations differed by health state but they are independent
of the treatment arm. The latter means that for each treatment
we assumed a different random variable but with the same
distribution parameters; that is, we get different sampling values
but on average they are the same. We assumed beta distributions
for the utilities and a gamma distribution for the costs. For details
on the probability distributions of each of the parameters
included in the model, we refer to Table 1. The cost-effective-
ness of new treatment compared with usual care was assessed by
using a cohort simulation analysis.Scenarios and Additional Sources of Uncertainty
We start with a reference scenario in which no additional
uncertainties are included in the model described above. Note
that this scenario represents the common situation at the time a
reimbursement dossier is submitted to policymakers. On the basis
of this model (which is usually built on RCT data only), policy-
makers have to make a decision about conditional reimbursement.
Subsequent scenarios are built on the basis of additional uncer-
tainties that will arise in the outcomes studies to be carried out
during the period of conditional reimbursement. We assumed that
these uncertainties were anticipated by several hypothetical
policymakers. In general, the additional sources of uncertainty
that are relevant to consider will vary with each decision problem.
In the present analysis, we explored the inclusion of broadening of
indication, persistence, and compliance in the model. For the
translation of persistence and compliance into the model, we
followed the approach of Ström et al. [11].
Thus, in scenario 2, we assumed that policymaker
A suggested that broadening of indication may inﬂuence the
cost-effectiveness results after the period of conditional
Table 1 – Parameters in the model.
Category Description Distribution Distribution parameters Mean (95% credible interval)
Costs NDP: Maintenance
cost per health
state
Gamma Moderate: α ¼ 120,
β ¼ 5.00
Moderate: €600(€497–€709)
Severe: α ¼ 600, β ¼ 2.00 Severe: €1200(€1108–€1298)
Very severe: α ¼ 900, β ¼ 3.33 Very severe: €3000 (€2802–€3197)
Usual care:
Intervention
cost per cycle
Normal μ ¼ 175, σ ¼ 3 €175 (€169–€180)
New treatment:
Intervention
cost per cycle
Normal μ ¼ 225, σ ¼ 5 €225 (€215–€234)
Exacerbation cost Gamma α ¼ 150, β ¼ 13.33 €2000 (€1692–€2330)
Utilities Utility per health
state
Beta Moderate: α ¼ 320, β ¼ 80 Moderate: 0.80 (0.76–0.83)
Severe: α ¼ 175, β ¼ 75 Severe: 0.70 (0.65–0.74)
Very severe: α ¼ 100, β ¼ 100 Very severe: 0.50 (0.45–0.54)
Utility change due
to exacerbation
Beta α ¼ 75, β ¼ 50 0.60 (0.51–0.68)
Exacerbation
probabilities
NDP exacerbation
probabilities
Beta Moderate: α ¼ 20, β ¼ 190 Moderate: 0.09 (0.05–0.13)
Severe: α ¼ 20, β ¼ 90 Severe: 0.18 (0.11–0.25)
Very severe: α ¼ 60, β ¼ 45 Very severe: 0.57 (0.47–0.66)
Usual care
exacerbation
probabilities
Beta Moderate: α ¼ 10, β ¼ 190 Moderate: 0.05 (0.0.2–0.08)
Severe: α ¼ 10, β ¼ 90 Severe: 0.10 (0.04–0.16)
Very severe: α ¼ 30, β ¼ 45 Very severe: 0.40 (0.29–0.51)
New treatment
exacerbation
probabilities
Beta Moderate: α ¼ 6, β ¼ 194 Moderate: 0.03 (0.00–0.04)
Severe: α ¼ 5, β ¼ 95 Severe: 0.05 (0.01–0.09)
Very severe: α ¼ 15, β ¼ 60 Very severe: 0.20 (0.12–0.29)
Transition
probabilities
NDP: Moderate to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (1600, 200, 120,
80)
Moderate to Moderate: 0.80 (0.78–0.81)
Moderate to Severe: 0.10 (0.084–0.11)
Moderate to Very severe: 0.06 (0.05–0.07)
Moderate to Dead: 0.04 (0.03–0.05)
NDP: Severe to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (200, 650, 100,
50)
Severe to Moderate: 0.20 (0.17–0.22)
Severe to Severe: 0.62 (0.55–0.67)
Severe to Very severe: 0.10 (0.08–0.11)
Severe to Dead: 0.05 (0.03–0.06)
NDP: Very severe
to (Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (75, 150, 450,
75)
Very severe to Moderate: 0.10 (0.07–0.12)
Very severe to Severe: 0.20 (0.17–0.22)
Very severe to Very severe: 0.60 (0.56–0.63)
Very severe to Dead: 0.10 (0.08–0.12)
Usual care:
Moderate to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (1700, 160, 80,
60)
Moderate to Moderate: 0.85 (0.83–0.86)
Moderate to Severe 0.08 (0.06–0.09)
Moderate to Very severe: 0.04 (0.03–0.05)
Moderate to Dead: 0.03 (0.02–0.04)
Usual care: Severe
to (Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (200, 670, 90,
40)
Severe to Moderate: 0.20 (0.17–0.22)
Severe to Severe: 0.67 (0.64–0.69)
Severe to Very severe: 0.09 (0.07–0.10)
Severe to Dead: 0.04 (0.03–0.05)
Usual care: Very
severe to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (75, 150, 465,
60)
Very severe to Moderate: 0.10 (0.08–0.12)
Very severe to Severe: 0.20 (0.17, 0.23)
Very severe to Very severe: 0.62 (0.58–0.65)
Very severe to Dead: 0.08 (0.06–0.10)
New treatment:
Moderate to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (1800, 100, 60,
40)
Moderate to Moderate: 0.90 (0.88–0.91)
Moderate to Severe: 0.05 (0.04–0.06)
Moderate to Very severe: 0.03 (0.02–0.04)
Moderate to Dead: 0.02 (0.01–0.02)
New treatment:
Severe to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (230, 680, 60,
30)
Severe to Moderate: 0.23 (0.20–0.25)
Severe to Severe: 0.68 (0.65–0.70)
Severe to Very severe: 0.06 (0.04–0.07)
Severe to Dead: 0.03 (0.02–0.04)
continued on next page
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Table 1 – continued
Category Description Distribution Distribution parameters Mean (95% credible interval)
New treatment:
Very severe to
(Moderate,
Severe, Very
severe, Dead)
Dirichlet (α1, α2, α3, α4) ¼ (75, 187.5, 435,
52.5)
Very severe to Moderate: 0.10 (0.08–0.12)
Very severe to Severe: 0.25 (0.21–0.28)
Very severe to Very severe: 0.58 (0.54–0.61)
Very severe to Dead: 0.07 (0.05–0.08)
Compliance Fraction of beneﬁt Beta α ¼ 52, β ¼ 13 0.8 (0.69–0.88)
Broadening of
indication
Percentage of
increased
moderate
patients
Normal
(truncated
at 0)
μ ¼ 0.30, σ ¼ 0.10 0.30 (0.10–0.50)
Persistence Usual care: Drop-
out probability
at cycle 1*
Beta α ¼ 31.8, β ¼ 568.2 0.053 (0.00–0.46)
New treatment:
Drop-out
probability at
cycle 1
Beta α ¼ 420, β ¼ 180 0.161 (0.00–0.72)
NDP, natural disease progression.
* The drop-out probability at cycle k ¼ 2, 3, …, 36 is assumed to follow a beta distribution with parameters α/k and β/k, where α and β are the
parameters of the beta distribution used to model the drop-out probability at cycle 1 that are shown in Table 1.
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indication (for the new treatment only) in the model. What often
happens when indication is broadened is that a greater propor-
tion of the less severe patients become eligible for treatment. On
average, it was proposed to increase the proportion of moderate
patients by 30% of the patients who originally were in severe and
very severe states. Researchers parameterized this according to a
normal distribution with mean 0.3 and standard deviation (SD)
0.1. Proportions of severe and very severe patients were then
decreased according to their share of the initial severity
distribution.
In scenario 3, it was assumed that a different policymaker B
proposed the inclusion of persistence only as an extra source of
uncertainty. Researchers modeled persistence as the probability
of dropping out of the treatment. A drop-out probability that is
decreasing over time was assumed. In particular, a mean drop-
out probability per cycle equal to p/k was considered, where p is
the initial drop-out probability and k ¼ 1… 36 is the cycle (month)
number. Researchers added unequal drop-out probabilities in
both treatment groups: a drop-out probability of 50% after 3 years
for new treatment (i.e., 16.1% in the ﬁrst cycle) and a drop-out
probability of 20% after 3 years for usual care (i.e., 5.3% in the ﬁrst
cycle). For each cycle, the drop-out probability is assumed to
follow a beta distribution (see Table 1 for details). It was also
assumed that when a patient drops out, the beneﬁt of the
treatment stops immediately and the patient returns to the
natural disease progression. Therefore, costs and effects of a
treatment are considered only until a patient drops out.
Another policymaker C advised the researchers to include
only low compliance for the new treatment. This was modeled in
scenario 4 by introducing the variable fraction of the treatment
beneﬁt (FOB) obtained because of not taking the medication as it
had been indicated. Researchers assumed that a low FOB
decreases the probability of moving to (or staying in) the moder-
ate health state and increases the probability of experiencing an
exacerbation. In fact, the beneﬁt of the new treatment is modeled
as a relative risk (RR) compared with usual care and multiplied
with the FOB parameter. All the exacerbation probabilities were
changed according to the factor RR  FOB. In the case of
transition probabilities, only the probability of moving to (orstaying in) the moderate state was changed by this new factor
(RR  FOB). The probability of moving to (or staying in) the
remaining health states is adjusted according to proportions of
the original Dirichlet distributions. A mean FOB equal to 0.8 was
considered. For details on the distribution used to model the FOB
parameter, we refer to Table 1.
Finally, in scenario 5, the more meticulous policymaker D
suggested the parameterization of all these new sources of
uncertainties at the same time.
All the scenarios deﬁned above were then compared following
a two-step approach. Researchers ﬁrst performed a probabilistic
sensitivity analysis (PSA) [12–15] and computed the associated
cost-effectiveness acceptability curve (CEAC) [16–18] and the
expected value of perfect information (EVPI) curve for all scenar-
ios. (All these results are based on a PSA sample size of 5000.) The
results of these analyses were compared with those in the
reference scenario to quantify the effect on the overall uncer-
tainty after introducing additional parameters. Priorities for
further research can be established (at least theoretically) via
the expected value of partial perfect information (EVPPI) [19,20]
because the EVPPI measures the relative importance of a certain
group of parameters compared with the other ones. Although
alternatives to the EVPPI have been recently proposed for priori-
tization of additional research [21], it was decided to use the
EVPPI ranking because it is a well-established procedure [2,22].
Therefore, researchers performed an EVPPI analysis on the
reference scenario and on those scenarios that, based on the
changes in cost-effectiveness results, were suspected to inﬂuence
priority setting for further research most. The EVPPI results were
compared to illustrate how priorities for further research may
change when additional uncertainties are included in the model.Results
Cost-Effectiveness Results
Cost-effectiveness results of all scenarios are summarized in
Table 2. The cost-effectiveness plane and the CEAC for the
reference scenario, in which no additional uncertainties were
Table 2 – Cost-effectiveness results for all scenarios.
Scenarios QALYs:
New
Costs:
New (€)
QALYs:
Usual
Costs:
Usual (€)
ICER
(€)
CE probability
at λ ¼ €40,000
Limit CE
probability
Decision
Reference
scenario: No
additional
parameters
1.40 8,281 1.08 6,606 5,360 0.99 0.99 Adopt new
Scenario 2:
Broadening of
indication (30%)
included
1.41 8,284 1.08 6,606 5,173 0.99 0.99 Adopt new
Scenario 3: Drop-
out probability
(50% new, 20%
usual) included
1.38 9,003 1.08 6,936 6,913 0.99 0.99 Adopt new
Scenario 4:
Fraction of
beneﬁt (80%)
included
1.13 8,307 1.08 6,605 35,827 0.51 0.60 Adopt new
Scenario 5: All
additional
parameters
included
1.13 9,028 1.08 6,940 42,586 0.48 0.61 Adopt
usual
CE, cost-effectiveness; λ ¼ threshold ICER; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
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the model that would be used to make a decision if policymakers
had not been aware of potentially relevant additional uncertain-
ties. Assuming a cost-effectiveness threshold (λ) equal to €40,000,
the new treatment was chosen as optimal because the estimated
incremental cost-effectiveness ratio (ICER) (€5360/QALY) was in
the northeast quadrant of the cost-effectiveness plane and it was
smaller than λ. At λ equal to €40,000, the cost-effectiveness
probability for the new treatment was 0.99.
The inclusion of the broadening of indication parameter (sce-
nario 2) had a small impact on cost-effectiveness results. The ICER
(€5173/QALY) was slightly lower than the ICER in the referenceFig. 1 – Cost-effectiveness plane (left) and CEAC (right) for the rscenario so that for policymaker A the decision did not change.
Furthermore, the probability of being cost-effective for the new
treatment at λ equal to €40,000 was also 0.99 (CEAC not shown). Note
that including the broadening of indication in the model resulted in
a better ICER. This is because in our model moderate patients have
more beneﬁt from treatment than do more severe patients.
The impact of including the drop-out probability parameter
(scenario 3) on cost-effectiveness results was larger than the
impact of including the broadening of indication parameter (sce-
nario 2). The ICER (€6913/QALY) was about €1500 higher than the
ICER in the reference scenario but was still low compared with the
threshold ICER of €40,000. Policymaker B will still choose the neweference scenario (no additional uncertainties included).
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the new treatment at λ equal to €40,000 was 0.99 (CEAC not shown).
Lowering compliance (scenario 4) had a strong impact on cost-
effectiveness results. It increased the expected costs of the new
treatment and reduced the expected QALYs gained. The ICER
(€35,827/QALY) was almost 7 times larger than the one in the
reference scenario but nevertheless lower than €40,000 per QALY.
Thus, for policymaker C, the new treatment was still acceptable.
At λ equal to €40,000, the cost-effectiveness probability for the
new treatment was 0.51 and converged to 0.60 as λ increased,
which illustrates the large uncertainty around the decision.
Finally, we observed that cost-effectiveness results from
scenario 5 (with the three additional parameters included in the
model) were similar to those in scenario 4. At λ equal to €40,000,Fig. 2 – Comparison of EVPI curves: reference scenario (no additio
(top-left), vs. scenario with drop out probability (top-right), vs. sce
the additional uncertainties (bottom-right).the cost-effectiveness probability for the new treatment was 0.48
and converged to 0.61 as λ increased. In this case, the ICER
(€42,586/QALY) was higher than €40,000 per QALY and therefore
policymaker D will choose the usual treatment as optimal.
Cost-effectiveness results from the different scenarios seem
to suggest that compliance and broadening of indication will
have high and low EVPPI values, respectively, whereas this is
unclear for drop-out probability.
VOI Results
We ﬁrst compared the EVPI curve of the reference scenario (with
no additional uncertainties) with the EVPI curves of all the
additional scenarios. This way we can easily quantify how thenal uncertainties) vs. scenario with broadening of indication
nario with compliance (bottom-left) and vs. scenario with all
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parameters separately in the model (scenarios 2–4) and after
including all of them altogether (scenario 5).
The EVPI curve of the model with broadening of indication for
policymaker A (Fig. 2, top-left) was almost identical to the EVPI
curve of the reference scenario. The EVPI curve of the model
including drop-out probability for policymaker B (Fig. 2, top-right)
was very similar to the EVPI curve of the reference scenario at
values of λ smaller than the ICER of the reference scenario (€5360/
QALY). But at larger values of λ, the EVPI curve of the model with
a drop-out probability was higher (unless both are 0) than the
EVPI curve of the reference scenario. In particular, the maximum
estimated EVPI for the reference scenario was €202, whereas the
maximum estimated EVPI for the scenario with a drop-out
probability was €332. The great impact of compliance on the
overall EVPI can be seen in the EVPI curves of scenario 4 for
policymaker C (Fig. 2, bottom-left) and scenario 5 for policymaker
D (Fig., 2, bottom-right), which were both very similar. For
example, in scenario 4, the EVPI was higher for the reference
scenario at values of λ approximately smaller than €8500. But at
larger values of λ, the EVPI in the model that included compliance
was much larger. In particular, at λ equal to €40,000, the EVPI was
more than 200 times higher than in the reference scenario.
Note that the EVPI curves of the different scenarios seem to
conﬁrm what we anticipated from cost-effectiveness results: that
the value of further investigating compliance and broadening of
indication is expected to be high and low, respectively, whereas
this remains unclear for the drop-out probability. Based on these
results, suppose that policymaker A concluded that there is no
reason for adjusting priority setting on the basis of the inclusion of
broadening of indication. The other policymakers addressed the
need for further research with the results of the EVPPI analyses
performed on the decision models from their respective scenarios.
EVPPI analyses were performed to assess two different ques-
tions. First, we compared the EVPPI curves of the reference
scenario (because the results of this model would be used to
make a decision if policymakers had not been aware of additional
uncertainties) and scenario 5 (because the model with all the
additional uncertainties is usually used to make a decision after
the period of conditional reimbursement) to illustrate how prior-
ities for further research may change when all additional param-
eters were considered. Then, we also compared the EVPPI curves
of scenarios 3 (with drop-out probability only) and 4 (with
compliance only) with those in scenario 5 (with all additional
uncertainties) to determine whether, on the basis of these two
simpler models, policymakers B and C would come to the same
prioritization of further research as policymaker D with the more
complex model in scenario 5.
In the reference scenario, there were four groups of input
parameters: transition probabilities, utilities, costs, and exacerbation
probabilities. The corresponding EVPPI curves are shown in Figure 3
(top-left) as a function of λ. Transition probabilities were identiﬁed
as the most important group of parameters because they had the
highest EVPPI. The EVPPI curves for utilities and costs were almost
identical, and the EVPPI curve for exacerbation probabilities was
slightly lower than these two. After all the additional parameters
were included in the model, as can be seen in Figure 3 (bottom-
right), transition probabilities was still the most important group but
compliance (modeled as the FOB parameter) became more relevant
than utilities for all values of λ. The relative importance of the
remaining groups of parameters, with the exception of broadening
of indication (for which the EVPPI values were always 0), depends on
λ. Thus, based on the EVPPI value at λ equal to €40,000, the following
ranking of groups of parameters could be established: transition
probabilities (€906), fraction of the beneﬁt (€499), drop-out proba-
bility (€235), utilities (€182), exacerbation probabilities (€49), costs
(€0), and broadening of indication (€0). Note also that in the presenceof additional uncertainties, the EVPPI for the other groups of
parameters (that were already in the reference scenario) may also
increase, as occurred here with transition probabilities and (to a
smaller extent) with utilities. There was no added value, however, in
including the broadening of indication parameter in the EVPPI
analyses.
Finally, we studied whether with the simpler models from
scenarios 3 and 4, policymakers B and C would come to the same
prioritization of further research as policymaker D with the
model with all the additional uncertainties included. The EVPPI
curves of the model in which only the drop-out probability
(scenario 3) was included (Fig. 3, top-right) showed that the
relative importance of the different groups of parameters
depends on λ. Transition probabilities and the drop-out proba-
bility seem to be in general the most important parameters in
this scenario, and both have similar EVPPI curves. On the basis of
this, policymaker B would conclude that for this model, the drop-
out probability is almost as important as transition probabilities,
which could not be anticipated from cost-effectiveness/EVPI
results. This is very different, however, from what policymaker
D would conclude on the basis of the EVPPI curves in scenario 5
(Fig. 3, bottom-right). In scenario 5, the EVPPI curves of both
transition probabilities and the FOB parameter are much higher
than the EVPPI curve of the drop-out probability and, depending
on λ, the EVPPI curve of the utilities can also be higher than this
one. Therefore, except for the hypothetical situation in which
additional research only on transition probabilities would be
recommended, policymakers B and D would never come to the
same prioritization. With the EVPPI curves of the model in which
only the FOB parameter (scenario 4) was included (Fig. 3, bottom-
left), policymaker C could establish a clear ranking of groups of
parameters, that is, transition probabilities, FOB, utilities, exac-
erbation probabilities, and costs. For some values of λ, policy-
maker D would come to the same ranking on the basis of the
EVPPI curves in scenario 5 (Fig. 3, bottom-right), especially at
values of λ for which the EVPPI curve of the drop-out probability is
very low or 0. There are, however, also values of λ at which the
drop-out probability becomes very relevant for policymaker D. In
these cases, policymaker D will not come to the same prioritiza-
tion as policymaker C.Discussion
In the Dutch conditional reimbursement setting, outcomes stud-
ies are required to collect data on actual effectiveness in daily
practice (instead of efﬁcacy—usually provided by RCTs) of a new
health care technology. The cost-effectiveness of these new
technologies is assessed with the help of decision models. These
models usually model what was observed in registration RCTs,
and in general little attention is paid to translating the trial
efﬁcacy into real-life effectiveness. The focus of this article was
on determining the impact of including additional parameters at
the time a decision is made about conditional reimbursement
(i.e., before the outcomes studies have been carried out), which
account for the additional uncertainties about cost-effectiveness
that will arise in outcomes studies and that are not present (or
minimized) in RCTs.
After studying all the scenarios above, we concluded that
transition probabilities were the most important parameters for
this model. Regarding the newly introduced uncertainties (and
under the assumptions we made), the broadening of indication
had little impact on the overall uncertainty, whereas compliance
and persistence were clearly important when establishing prior-
ities for further research. The cost-effectiveness results showed
that the most important differences with respect to the reference
scenario were due to the parameterization of compliance in the
Fig. 3 – EVPPI curves for the reference scenario (top-left), for the scenario with drop out probability (top-right), for the scenario
with compliance (bottom-left) and for the scenario with all the additional uncertainties (bottom-right).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 0 – 1 0 9 107decision model. Thus, policymakers might (wrongly) conclude
that there is little value in adding the broadening of indication
and drop-out probability parameters to the decision model. We
would like to emphasize, however, that this can only be con-
cluded after all the additional uncertainties have been para-
meterized because policymakers cannot know upfront whether
and to what extent these additional uncertainties are relevant or
not. For instance, policymaker A could not be sure that the
inclusion of broadening of indication would not change priority
setting based on only the EVPI. Likewise, policymaker B would
not have known that compliance might be important because he
or she never thought about including it in the model.
It is clear that priorities for further research can be very
different in the RCT-based model and the outcomes studies
model not only because new uncertainties are going to beprioritized but also because the RCT-related uncertainties may
interact with the new ones and their relative importance may
increase. As we have seen in our study, the inclusion of addi-
tional uncertainties also increased the value of conducting
further research about transition probabilities. Thus, if the need
for additional research and its prioritization are going to be
assessed at the beginning of the period of conditional reimburse-
ment solely on the basis of the RCT-based model, the decisions
can be very wrong.
We have related the additional uncertainties arising from an
outcomes study to several adherence concepts. In particular, we
have considered persistence, compliance, and broadening of
indication as our extra uncertainties observed in an outcomes
study. Because these additional uncertainties are not unique,
judgment must be used to decide what kind and howmany of the
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 0 – 1 0 9108additional uncertainties are relevant to the model under consid-
eration. Moreover, there are different ways to operationalize
these additional uncertainties, which also constitutes a source
of uncertainty that is hard to deal with. For example, in our
model, moderate patients have more beneﬁt from treatment than
do more severe patients, which does not reﬂect the way we
usually think about indication broadening: it worsens the ICER
because less severe patients commonly have less beneﬁt from
treatment. Note also that in our model persistence was imple-
mented as the probability of dropping out of the treatment in
each time cycle. We chose a drop-out probability that decreased
over time, implying that most of the dropouts occur in the ﬁrst
cycles. We may expect that with another implementation its
impact on cost-effectiveness results could be different. Moreover,
we assumed that when a patient drops out, the disease is driven
by natural disease progression, which is the same independently
of the treatment arm that the patient followed. Thus, when drop-
out probabilities are considered, the difference in net beneﬁt
between the two treatments is determined basically by the
number of patients who did not drop out, that is, by the choice
made for the initial drop-out probability for both new and usual
treatments. When different values were selected, the results (not
shown) were also slightly different. It is important to realize that
adding these additional parameters leads to yet another set of
parameters for which reliable estimates need to be found. Quite
often, such data will not be available for exactly the treatment
and indication under consideration at the time the reimburse-
ment dossier is submitted. There is published literature available,
however, on persistence and adherence for various types of
treatment (curative, prevention) and diseases, which may be
helpful. In addition, patient registries and pharmacoepidemio-
logical databases may be used as a source of information.
Note that we are not judging which model is the best one
among a set of potentially good models, which are based on
different structural assumptions, to inform a given decision
problem. This is addressed for example by Strong et al. [23]. They
quantify the uncertainty associated with the model structure by
introducing a discrepancy term that quantiﬁes the structural
error, that is, how much the model outputs deviate from the
true (unknown) outputs. They also explicitly distinguish between
PSA, which quantiﬁes the uncertainty in the model output due to
the uncertainty in model inputs, and model discrepancy. In our
article, we consider additional uncertainties as new input param-
eters of the model, which are then included in the PSA (and VOI
analyses). Thus, rather than studying model discrepancy, our
focus is on studying how the uncertainty in the model output
(due to uncertainty in the model inputs) affects the decision to be
made by the policymaker. On the basis of our experience with
reimbursement dossiers, we know that the models included in
those dossiers usually try to mimic what is observed in RCTs as
closely as possible, which usually does not properly represent
daily practice. Therefore, the model used at the time the decision
on conditional reimbursement has to be made is usually wrong
because it does not account for uncertainties arising in daily
practice.
It is important to recognize that the need for further research
can be well informed only by using the expected value of sample
information (EVSI) and the expected net beneﬁt of sampling
rather than the EVPI as established in Eckermann et al. [24].
Our concept of prioritization, however, is different than the one
in the article by Eckermann et al. [24] in which different
technologies are prioritized according to the expected net beneﬁt
of sampling (and not according to the EVPI) until a certain
available budget is consumed. For us prioritization takes place
within a particular technology, in which we focus on (a group of)
input parameters, and it requires partial methods. This issue is
not addressed by Eckermann et al. [24] because they state thattheir methodology does not allow partial analyses, for which they
further refer to Ades et al. [25]. There it is established that the
estimated EVPI and EVPPI set an upper limit on the societal
returns to further research, that is, a theoretical value of infor-
mation that can be achieved only by an inﬁnitely large sample. In
practice, the partial EVSI should be computed and compared with
the costs of obtaining the samples, which in fact would inform
the real priorities for further research. We have, however, opted
in our article for the theoretical priorities (and therefore the EVPPI)
for two main reasons. The ﬁrst and foremost is that choosing partial
EVSI instead of partial EVPI methods does not change our main
objective, which is to study the impact of the uncertainties that may
become relevant after the years of conditional reimbursement at the
time the decision is made. The second reason for choosing EVPPI
methods was more practical because the computation of the EVPPI
is less burdensome than the computation of the EVSI and the
expected net beneﬁt of sampling.
Finally, we also emphasize that heterogeneity must be con-
sidered when an outcomes study is designed. In daily practice,
the patient population may be broadened, leading to a more
heterogeneous population in an outcomes study than in an RCT.
As a result, the treatment effect observed in an outcomes study
may differ from the one observed in an RCT. Although this
difference in treatment effect has been modeled in our article
with an additional input parameter, the most common approach
would be to perform a patient-level simulation analysis [10,26].
Thus, accounting explicitly for heterogeneity would change the
methods considered in our article. To predict, however, how
heterogeneity might affect the results of our article is hard to
quantify. In general, we may expect higher uncertainty on
parameters associated with effectiveness because RRs or odds
ratios from RCTs may not be representative for outcomes studies.
Nevertheless, the extent to which these may increase would
depend on the assumptions made and how these were imple-
mented in the new model. In line with Grutters et al. [27], further
analyses to study patient heterogeneity could also be performed.
Overall, we conclude that the usual practice of modeling only
RCT data at the time the decision on conditional reimbursement
has to be made can lead to wrong decisions. It is important to
anticipate at an early stage additional uncertainties arising from
outcomes studies (e.g., future dropout, compliance, and indica-
tion) and include them in the model at the time the decision on
conditional reimbursement has to be made because the value of
investigating these elements during the outcomes study may be
very high. Note also that the inclusion of additional uncertainties
in the model can produce very different EVPPI values for the
other uncertainties already considered, which can also have a
strong impact on the prioritization of further research. Therefore,
it is essential for decision-making purposes to incorporate all
these additional uncertainties into the decision modeling
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